Identification of Novel Pancreatic Lipase Inhibitors Using In Silico Studies

Author(s): Umesh Panwar, Sanjeev Kumar Singh*.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets

Volume 19 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Obesity is well known multifactorial disorder towards the public health concern in front of the world. Increasing rates of obesity are characterized by liver diseases, chronic diseases, diabetes mellitus, hypertension and stroke, improper function of the heart, reproductive and gastrointestinal diseases, and gallstones. An essential enzyme pancreatic lipase recognized for the digestion and absorption of lipids can be a promising drug target towards the future development of antiobesity therapeutics in the cure of obesity disorders.

Objective: The purpose of present study is to identify an effective potential therapeutic agent for the inhibition of pancreatic lipase.

Methods: A trio of in-silico procedure of HTVS, SP and XP in Glide module, Schrodinger with default parameters, was applied on Specs databases to identify the best potential compound based on receptor grid. Finally, based on binding interaction, docking score and glide energy, selected compounds were taken forward to the platform of IFD, ADME, MMGBSA, DFT, and MDS for analyzing the ligands behavior into the protein binding site.

Results: Using in silico protocol of structure-based virtual screening on pancreatic lipase top two compounds AN-465/43369242 & AN-465/43384139 from Specs database were reported. The result suggested that both the compounds are competitive inhibitors with higher docking score and greatest binding affinity than the reported inhibitor.

Conclusion: We anticipate that results could be future therapeutic agents and may present an idea toward the experimental studies against the inhibition of pancreatic lipase.

Keywords: Obesity, pancreatic lipase, virtual screening, docking, simulation, ADME.

[1]
Kopelman, P.G. Obesity as a medical problem. Nature, 2000, 404(6778), 635-643.
[2]
Cairns, E. Obesity: the fat lady sings? Drug Discov. Today, 2005, 10(5), 305-307.
[3]
Trigueros, L.; Peña, S.; Ugidos, A.V.; Sayas-Barberá, E.; Pérez-Álvarez, J.A.; Sendra, E. Food ingredients as anti-obesity agents: A review. Crit. Rev. Food Sci. Nutr., 2013, 53(9), 929-942.
[4]
Jebb, S. Obesity: causes and consequences. Women’s. Health Med., 2004, 1, 38-41.
[5]
Calle, E.E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003, 348(17), 1625-1638.
[6]
Finer, N. Medical consequences of obesity. Medicine (Baltimore), 2006, 34, 510-514.
[7]
Shi, Y.; Burn, P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat. Rev. Drug Discov., 2004, 3(8), 695-710.
[8]
de, la, Garza, A.L.; Milagro, F.I.; Boque, N.; Campión, J.; Martínez, J.A. Natural inhibitors of pancreatic lipase as new players in obesity treatment. Planta Med., 2011, 77, 773-785.
[9]
Kang, J.G.; Park, C.Y. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab. J., 2012, 36(1), 13-25.
[10]
Bourne, Y.; Martinez, C.; Kerfelec, B.; Lombardo, D.; Chapus, C.; Cambillau, C. Horse pancreatic lipase. The crystal structure refined at 2.3 A resolution. J. Mol. Biol., 1994, 238(5), 709-732.
[11]
Van, T.H.; Sarda, L.; Verger, R.; Cambillau, C. Structure of the pancre¬atic lipase-procolipase complex. Nature, 1992, 359, 159-162.
[12]
Birari, R.B.; Bhutani, K.K. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov. Today, 2007, 12(19-20), 879-889.
[13]
Panwar, U.; Singh, S.K. Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75). J. Biomol. Struct. Dyn., 2018, 36(12), 3199-3217.
[14]
Reddy, K.K.; Singh, S.K. Combined ligand and structure-based approaches on HIV-1 integrase strand transfer inhibitors. Chem. Biol. Interact., 2014, 218, 71-81.
[15]
Aarthy, M.; Panwar, U.; Selvaraj, C.; Singh, S.K. Advantages of Structure-Based Drug Design Approaches in Neurological Disorders. Curr. Neuropharmacol., 2017, 15(8), 1136-1155.
[16]
Panwar, U.; Singh, S.K. An Overview on Zika Virus and the Importance of Computational Drug Discovery. J. Expl. Res. Pharm., 2018, 3, 43-51.
[17]
Egloff, M.P.; Marguet, F.; Buono, G.; Verger, R.; Cambillau, C.; van Tilbeurgh, H. The 2.46 A resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl phosphonate. Biochemistry, 1995, 34(9), 2751-2762.
[18]
Specs Chemical Database. Available at: http://www.specs.net/snpage.php?snpageid=home (Accessed November 1, 2017).
[19]
Protein Preparation Wizard; Schrödinger, LLC: New York, NY, 2015.
[20]
Jorgensen, W.L.; Maxwell, D.S.; Tirado-Rives, J. Development and Testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc., 1996, 118, 11225-11236.
[21]
Reddy, K.K.; Singh, P.; Singh, S.K. Blocking the interaction between HIV-1 integrase and human LEDGF/p75: Mutational studies, virtual screening and molecular dynamics simulations. Mol. Biosyst., 2014, 10(3), 526-536.
[22]
Selvaraj, C.; Priya, R.B.; Lee, J.K.; Singh, S.K. Mechanistic Insights of SrtA-LPXTG Blockers targeting the transpeptidase mechanism in Streptococcus mutans. RSC Advances, 2015, 5, 100498-100510.
[23]
Glide; Schrödinger, LLC: New York, NY, 2015.
[24]
LigPrep; Schrödinger, LLC: New York, NY, 2015.
[25]
Singh, S.; Vijaya Prabhu, S.; Suryanarayanan, V.; Bhardwaj, R.; Singh, S.K.; Dubey, V.K. Molecular docking and structure-based virtual screening studies of potential drug target, CAAX prenyl proteases, of Leishmania donovani. J. Biomol. Struct. Dyn., 2016, 34(11), 2367-2386.
[26]
Suryanarayanan, V.; Singh, S.K. Assessment of dual inhibition property of newly discovered inhibitors against PCAF and GCN5 through in silico screening, molecular dynamics simulation and DFT approach. J. Recept. Signal Transduct. Res., 2015, 35(5), 370-380.
[27]
Sherman, W.; Beard, H.S.; Farid, R. Use of an induced fit receptor structure in virtual screening. Chem. Biol. Drug Des., 2006, 67(1), 83-84.
[28]
Prime; Schrödinger, LLC: New York, NY, 2015.
[29]
Lyne, P.D.; Lamb, M.L.; Saeh, J.C. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J. Med. Chem., 2006, 49(16), 4805-4808.
[30]
QikProp; Schrödinger, LLC: New York, NY, 2015.
[31]
Jaguar; Schrödinger, LLC: New York, NY, 2015.
[32]
Adcock, S.A.; McCammon, J.A. Molecular dynamics: Survey of methods for simulating the activity of proteins. Chem. Rev., 2006, 106(5), 1589-1615.
[33]
Durrant, J.D.; McCammon, J.A. Molecular dynamics simulations and drug discovery. BMC Biol., 2011, 9, 71.
[34]
Tripathi, S.K.; Singh, S.K. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: Prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation. Mol. Biosyst., 2014, 10(8), 2189-2201.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 4
Year: 2019
Page: [449 - 457]
Pages: 9
DOI: 10.2174/1871530319666181128100903
Price: $58

Article Metrics

PDF: 23
HTML: 3